BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Merkel Cell Carcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Merkel Cell Carcinoma
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04261855-2017@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Avelumab: Phase 1/2 readout est. (NCT04261855)
DESCRIPTION:Avelumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: Targeted 
 Therapy and Avelumab in Merkel Cell Carcinoma\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ave
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04261855
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05496036-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05496036)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Neoadj
 uvant PD-1 Blockade in Resectable Merkel Cell Carcinoma\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05496036
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03712605-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03712605)
DESCRIPTION:Pembrolizumab\, phase 3\, Merkel Cell Carcinoma.\nStudy: Testin
 g Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma 
 After Surgery\, STAMP Trial\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03712605
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06056895-2210@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT06056895)
DESCRIPTION:Retifanlimab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Triple 
 Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory
  Merkel Cell Carcinoma\nEstimated primary completion: 31 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06056895
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04792073-2017@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Avelumab: Phase 2 readout est. (NCT04792073)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Study of Av
 elumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcin
 oma\nEstimated primary completion: March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/avelumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04792073
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947928-10880@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:IFx-2.0: Phase 2/3 readout est. (NCT06947928)
DESCRIPTION:IFx-2.0\, phase 2/3\, Merkel Cell Carcinoma.\nStudy: Placebo-Co
 ntrolled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibi
 tor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ifx-2-0#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06947928
URL:https://assetmemo.bio/drug/ifx-2-0#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06086288-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06086288)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Study 
 of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in T
 reatment naïve Advanced meRkel Cell cArcinoma (MCC)\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06086288
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947500-2017@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Avelumab: Phase 2 readout est. (NCT05947500)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Testing the
  Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Ev
 aluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer\
 , MATRiX Trial\nEstimated primary completion: 1 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05947500
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583708-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05583708)
DESCRIPTION:Pembrolizumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Phase 
 II Study of Peptide Receptor Radionuclide Therapy in Combination With Immu
 notherapy for Patients With Merkel Cell Cancer\nEstimated primary completi
 on: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05583708
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03271372-2017@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Avelumab: Phase 3 readout est. (NCT03271372)
DESCRIPTION:Avelumab\, phase 3\, Merkel Cell Carcinoma.\nStudy: Adjuvant Av
 elumab in Merkel Cell Cancer\nEstimated primary completion: 31 January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/avelumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03271372
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07302347-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07302347)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: A St
 udy of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors 
 or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (M
 K-3475-G21/KEYNOTE-G21)\nEstimated primary completion: 30 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07302347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2017@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Avelumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Avelumab\, phase 2\, Merkel Cell Carcinoma.\nStudy: QUILT-3.055
 : A Study of Combination Immunotherapies in Patients Who Have Previously R
 eceived Treatment With Immune Checkpoint Inhibitors\nEstimated primary com
 pletion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/avelumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03228667
URL:https://assetmemo.bio/drug/avelumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472322-2210@assetmemo.bio
DTSTAMP:20261121T004942Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT07472322)
DESCRIPTION:Retifanlimab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: ASTX7
 27 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-
 PD-(L)1\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07472322
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
